Scholz I, Oberwittler H, Riedel KD, et al. Pharmacokinetics, metabolism and bioavailability of the triazole antifungal agent voriconazole in relation to CYP2C19 genotype[J]. Br J Clin Pharmacol, 2009, 68(6): 906-915.
[2]
Shon JH, Yeo CW, Liu KH, et al. Itraconazole and rifampin alter significantly the disposition and antihistamine effect of ebastine and its metabolites in healthy participants[J]. J Clin Pharmacol, 2010, 50(2): 195-204.
[3]
Uttayamakul S, Likanonsakul S, Manosuthi W, et al. Effects of CYP2B6 G516T polymorphisms on plasma efavirenz and nevirapine levels when co-administered with rifampicin in HIV/TB co-infected Thai adults[J]. AIDS Res Ther, 2010, 7: 8.
[4]
Kim SH, Kim SH, Bahn JW, et al. Genetic polymorphisms of drug-metabolizing enzymes and anti-TB drug-induced hepatitis[J]. Pharmacogenomics, 2009, 10(11): 1767-1779.
Hersh EV, Moore PA. Drug interactions in dentistry: the importance of knowing your CYPs[J]. J Am Dent Assoc, 2004, 135(3): 298-311.
[16]
Chhun S, Verstuyft C, Rizzo-Padoin N, et al. Gefitinib-phenytoin interaction is not correlated with the C-erythromycin breath test in healthy male volunteers[J]. Br J Clin Pharmacol, 2009, 68(2): 226-237.
[17]
Galetin A, Gertz M, Houston JB. Contribution of intestinal cytochrome p450-mediated metabolism to drug-drug inhibition and induction interactions[J]. Drug Metab Pharmacokinet, 2010, 25(1): 28-47.
[18]
Vandenbrink BM, Isoherranen N. The role of metabolites in predicting drug-drug interactions: focus on irreversible cytochrome P450 inhibition[J]. Curr Opin Drug Discov Devel, 2010, 13(1): 66-77.
[19]
Zhang L, Wei MJ, Zhao CY, et al. Determination of the inhibitory potential of 6 fluoroquinolones on CYP1A2 and CYP2C9 in human liver microsomes[J]. Acta Pharmacol Sin, 2008, 29(12): 1507-1514.
[20]
Westphal JF. Macrolide-induced clinically relevant drug interactions with cytochrome P-450A (CYP) 3A4: an update focused on clarithromycin, azithromycin and dirithromycin[J]. Br J Clin Pharmacol, 2000, 50(4): 285-295.
[21]
Gr？nlund J, Saari T, Hagelberg N, et al. Effect of telithromycin on the pharmacokinetics and pharmacodynamics of oral oxycodone[J]. J Clin Pharmacol, 2010, 50(1): 101-108.
Granfors MT, Backman JT, Neuvonen M, et al. Ciprofloxacin greatly increases concentrations and hypotensive effect of tizanidine by inhibiting its cytochrome P450 1A2-mediated presystemic metabolism[J]. Clin Pharmacol Ther, 2004, 76(6): 598-606.
[25]
Shin KH, Kim BH, Kim TE, et al. The effects of ketoconazole and rifampicin on the pharmacokinetics of mirodenafil in healthy Korean male volunteers: an open-label, one-sequence, three-period, three-treatment crossover study[J]. Clin Ther, 2009, 31(12): 3009-3020.
[26]
Skerjanec A, Wang J, Maren K, et al. Investigation of the pharmacokinetic interactions of deferasirox, a once-daily oral Iron chelator, with midazolam, rifampin, and repaglinide in healthy volunteers[J]. J Clin Pharmacol, 2010, 50(2): 205-213.
